Coya Therapeutics appoints Dieter Weinand to its Board of Directors

– USA, TX –  Coya Therapeutics, Inc. (Nasdaq: COYA), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells, today announced the appointment of Dieter Weinand to its Board of Directors, effective immediately.

“Coya has strengthened its DNA with Dieter. Having his counsel, guidance, and network available to Coya at this time will bolster our profile in ‘big picture’ opportunities including business development and strategic discussions. His selection to join Coya at this point in his career is a validating moment for us,” said Dr. Howard Berman.

About Dieter Weinand

Dieter Weinand is an experienced executive with over 25 years of experience in the pharmaceuticals and biotech industries. Mr. Weinand presently serves as the Chairman of the Board of Directors of Replimune Group Inc. (NASDAQ: REPL), Mnemo Therapeutics, Umoja Biopharma, Inc., Inspirna, Inc., and Ziel Bio, Inc. Previously, Mr. Weinand was CEO and Chairman of the Board of Bayer Pharma AG and member of the Management Board at Bayer AG. Before his work at Bayer, Mr. Weinand held various positions in commercial, operational, and strategic areas of the pharmaceutical industry. These included responsibilities spanning various therapeutic areas and geographies for companies such as Pfizer, Bristol Myers Squibb, and Otsuka.

Mr. Weinand is a former board member of the Pharmaceutical Research and Manufacturers of America (PhRMA), the European Federation of Pharmaceutical Industries & Associations, and the International Federation of Pharmaceutical Manufacturers, and served as a member of the Board of Directors of HealthPrize Technologies.

“I am delighted to join the board of Coya, a company whose science has the potential to make a significant clinical difference in patients’ lives suffering from difficult-to-treat neurodegenerative diseases, an experienced leadership team that I believe can unlock the full potential of the therapies, and a cohesive board of directors. I look forward to becoming a part of this remarkable company,” said Dieter Weinand.

About Coya Therapeutics, Inc.

Coya Therapeutics, Inc. is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in a lack of homeostasis of the immune system. Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s lead therapeutic programs include Treg-enhancing biologics (COYA 300 Series product candidates) COYA 301 and COYA 302, which are intended to enhance Treg function and expand Treg numbers. COYA 301 is a proprietary investigational recombinant human low-dose IL-2 biologic for subcutaneous administration intended to enhance Treg function and expand Treg numbers in vivo, and COYA 302 is a dual-mechanism investigational biologic combination comprised of proprietary low-dose IL-2 and proprietary CTLA4 Ig. The low dose IL-2 is intended to enhance anti-inflammatory regulatory T cell function and numbers while the fusion protein CTLA4 Ig is intended to suppress pro-inflammatory cell function. These two mechanisms may be additive or synergistic in suppressing inflammation.

SOURCE: https://www.coyatherapeutics.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.